GSK, Spero Stop UTI Drug Trial After Early Success
(Reuters) -Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract infections early as the study met its main goal, the companies said on Wednesday.
Shares of Spero more than tripled to $2.24 in premarket trading.
The decision comes after a recommendation from an independent committee that completed an interim analysis of data from 1,690 patients enrolled in the trial.
The companies were studying the oral drug, tebipenem HBr, as a treatment for complicated urinary tract infections (cUTIs), including a type of kidney infection called pyelonephritis.
An estimated 2.9 million cases of cUTIs are treated annually in the U.S. alone.
The current standard of care includes antibiotics called carbapenem, but those are only available for intravenous administration.
In the trial, the drug showed it was at least as good as an intravenous imipenem-cilastatin, a type of antibiotic, in hospitalized adult patients.
If approved, the drug could be the first oral carbapenem antibiotic for patients with cUTIs.
The review by the committee did not identify any new safety concerns beyond what had been reported in other studies, with diarrhea and headache as the two most reported side effects.
The companies had entered into a licensing agreement for the development of tebipenem HBr in 2022.
The U.S. FDA had previously declined to approve the drug saying a late-stage study testing it was insufficient and an additional study would be required.
The British drugmaker plans to work with U.S. regulatory authorities to include the data as part of a filing in the second half of the year.
Full results will be submitted for presentation at an upcoming scientific congress and for publication in a peer-reviewed journal, the companies said.
(Reporting by Sriparna Roy and Yadarisa Shabong in Bengaluru; Editing by Devika Syamnath)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Popular sparkling water brand sold at Costco recalled due to possible contamination
A popular brand of sparkling water has issued a recall over possible contamination fears. On Monday, Coca-Cola sent a letter to Costco members announcing that they were voluntarily recalling Topo Chico Mineral Water due to the possible presence of Pseudomonas aeruginosa, a bacteria that occurs naturally in water sources, including mineral water. According to the letter sent to customers, the health risks of consuming mineral water with Pseudomonas are 'very low' in healthy individuals and will only cause 'minor health consequences' in people with 'weakened immune systems.' 'The safety and quality of the products we offer our consumers is our top priority,' the letter read. The recall specifically applies to bottles that were sold at select Costco warehouses in Texas and Louisiana from May 20 to May 29, 2025. The water bottles were sold in 18-packs and have the lot number 13A2541 printed on both the case's packaging and the neck of the individual bottles. Customers who have purchased the affected water bottles are urged to return them to their local Costco in exchange for a full refund. Any questions regarding the recall can be directed to Coca-Cola using the phone number 1-800-GET-COKE. The news of the recall comes a few days after an ongoing tomato recall had been elevated by the FDA after it found the contamination could lead to death. The initial voluntary recall of H&C Farms Label tomatoes was announced at the beginning of May when Williams Farms Repack LLC distributed the potentially contaminated tomatoes to wholesalers in South Carolina, North Carolina, and Georgia. Sold in different-sized packages, ranging from three-packs to 25-pound bags, the tomatoes were distributed between April 23 and 28, according to the FDA's notice. No illnesses were reported at the time. The New York Times reported that the FDA upgraded the recall last week to a Class I, described as 'a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.' At this time, the FDA doesn't expect that customers will come into contact with fresh tomatoes from the contaminated batch. However, customers may have frozen the tomatoes for future consumption. Salmonella bacteria can survive for weeks in a wet environment like a freezer. Customers are urged to throw away any affected tomatoes immediately. The source of the contamination is not known.
Yahoo
14 minutes ago
- Yahoo
Baby saved by gene-editing therapy 'graduates' from hospital, goes home
KJ Muldoon, a 10-month-old baby who sparked nationwide headlines after receiving a first-of-its kind gene-editing treatment, was released from the hospital this week. KJ has spent the majority of his life at Children's Hospital of Philadelphia after being diagnosed with a one-in-a-million, deadly genetic disease shortly after birth. Working quickly, his doctors were able to use new gene-editing technology called CRISPR, designing a bespoke treatment just for him. MORE: Doctors save baby's life with first-ever gene fix for deadly rare disease The treatment, first infused into his body at seven months old, seems to have worked. KJ's body, which was fighting a toxic buildup of ammonia, began to thrive and he quickly gained weight appropriate for a baby of his age. Wearing a cap and gown to symbolize his 'graduation' from the hospital, baby KJ was discharged home to his parents and siblings on Tuesday after spending 307 days at Children's Hospital of Philadelphia. Doctors and nurses gathered for a "clap out" on his way out the hospital doors, and he was escorted home by local law enforcement. KJ's metabolic condition, called carbamoyl-phosphate synthetase 1 deficiency, affects about 1 in 1.3 million people. The disease kills 50% of babies by early infancy. KJ 'had the most severe variant," Dr. Ahrens-Nicklas, one of KJ's doctors at Children's Hospital of Philadelphia, told ABC News. "This meant that we had to expedite the pathway for personalized therapy we were already working on," he said. Gene therapy treatments have already been approved for more common genetic diseases, including the blood disorders sickle cell disease and beta thalassemia, which affect tens of thousands of patients in the U.S. Those treatments are sold by major pharmaceutical and biotechnology companies. MORE: FDA approves gene therapies for sickle cell disease, a 'functional cure' for many KJ's disease is so rare that his doctors were on their own. But thanks to the technology available at Children's Hospital of Philadelphia, his doctors believed they could use a streamlined approach to make their own bespoke therapy, in-house. CRISPR gene-editing technology was the perfect tool for a rare genetic disease like KJ's, and potentially future babies born with slightly different genetic errors. "Think of it like a GPS signal," Dr. Kiran Musunuru, director of the Penn Cardiovascular Institute's Genetic and Epigenetic Origins of Disease Program, told ABC News. "You can change where the GPS is going depending on what specific sequence of genes you want to change." Musunuru says there is still a lot of work to be done on this bespoke treatment to make it feasible, but he is hopeful that more babies with ultra-rare conditions can be treated this way. ABC's Dr. Keerthana Pakanati contributed to this report.
Yahoo
38 minutes ago
- Yahoo
Mindset Medical Announces FDA Clearance for its Contactless Respiratory Rate Measurement Device
PHOENIX, June 4, 2025 /PRNewswire/ -- Mindset Medical, Inc. ("Mindset Medical" or the "Company"), a digital health company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its latest contactless vital sign monitoring solution. The Informed Vital Core (IVC) App is a software-only medical device that measures respiratory rate through smartphones, tablets, or laptop cameras. This milestone marks Mindset Medical's second FDA clearance in less than a year, building on the success of its previously cleared pulse rate measurement device on November 18, 2024. With these clearances, Mindset Medical is closer to transforming the delivery of care with innovative telehealth technology. Mindset Medical can now offer another solution for healthcare providers to gather physiological information from their patients without needing physical contact or dedicated hardware. Software on phones, tablets, and laptops can easily be deployed in clinical and outpatient facilities, remote care environments, long-term care settings, or the patient's home. Telemedicine skyrocketed due to COVID-19, as many barriers to adoption were removed, allowing video conferencing to become routine. "Video alone is not enough. Patients and providers deserve virtual services with fewer barriers and limitations because we are all patients at the end of the day. The next step is purpose-built virtual health offerings that can legitimately provide brick-and-mortar experiences. Virtual healthcare remains a permanent fixture moving forward, and we have only scratched the surface of how we use technology to address shortcomings with the health system."-- Mitch Foster, Chairman and CEO of Mindset Medical. Mindset Medical envisions a future where vital signs and diagnoses can be captured with nothing more than everyday devices. This will help bridge gaps in access to healthcare, reduce the burden on providers, and improve chances for earlier intervention. The company continues developing its platform to include additional vital sign measurements, working closely with clinicians and patients to ensure each new feature meets their needs. About Mindset Medical Mindset Medical, Inc. ( headquartered in Phoenix, AZ, was formed by several members of Excelsius Surgical, a robotic surgical platform. Recently, Mindset Medical has developed proprietary signal-processing algorithms that extract health measurements from video. Combined with AI technology for advanced image analysis and facial recognition, these algorithms transform patients' smartphones into contactless vital sign measurement devices. Mindset Medical utilizes secure and encrypted links delivered to patients from healthcare providers to collect up-to-the-minute patient data and accurate remote physiological measurements. Contact For media, sales, or investor inquiries, please email 396163@ or 396163@ We can also be reached at 480.269.0859. HASHTAGS#healthcare #telehealth #healthequity #vitals #physiological SOCIAL MEDIA PROFILESLinkedin: View original content: SOURCE Mindset Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
